Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14103621 | 0.91 | NAMPT (0.52) | NAMPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4884232 | 0.89 | ALDH1A1 (0.47) | NAMPTKDM4EALDH1A1 | |
| SCHEMBL4887300 | 0.89 | CFD (0.49) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL14087739 | 0.87 | KMT2A (0.44) | NAMPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4884292 | 0.84 | DHODH (0.45) | NAMPTKMT2AKDM4E | |
| SCHEMBL4896179 | 0.83 | RAB9A (0.58) | KMT2AKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4883875 | 0.81 | HDAC1 (0.40) | NAMPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4889436 | 0.81 | NPC1 (0.40) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL4894933 | 0.81 | DHODH (0.43) | NAMPTKMT2AMEN1KDM4E | |
| SCHEMBL4882720 | 0.80 | HTT (0.50) | KMT2AMEN1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | NAMPT 3087/4885KMT2A 2650/4885MEN1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.